onc Videos

Videos

Videos

Tafasitamab Plus Lenalidomide Therapy Demonstrates Prolonged, Durable Responses for Patients With R/R DLBCL

07/11/2023

Featuring Nagesh Kalakonda, MD

Featuring Nagesh Kalakonda, MD ...

Nagesh Kalakonda, MD, discusses final results from the L-MIND study, in which the combination of tafasitamab plus lenalidomide demonstrated durable responses and curative potential for patients with R/R DLBCL.

Nagesh Kalakonda, MD, discusses...

07/11/2023

Oncology

Videos

Post-Transplantation Cyclophosphamide, Tacrolimus, Mycophenolate and Mofetil vs Standard Prophylaxis for Patients With GVHD

07/10/2023

Featuring Javier Bolaños Meade, MD

Featuring Javier Bolaños Meade, MD ...

Javier Bolaños Meade, MD, presents insights from a phase 3 trial on post-transplantation cyclophosphamide, tacrolimus, mycophenolate and mofetil prophylaxis vs standard prophylaxis for patients with graft-versus-host-disease.

Javier Bolaños Meade, MD,...

07/10/2023

Oncology

Videos

Analyzing Mechanisms of Pirtobrutinib Resistance Among Patients With CLL Pre-Treated With a Covalent BTK Inhibitor

07/10/2023

Featuring Jennifer Brown, MD

At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.

At the 2023 EHA Congress,...

07/10/2023

Oncology

Videos

FDA Approval of Epcoritamab for Patients With R/R Diffuse Large B-Cell Lymphoma

07/06/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, shares insights into the recent FDA approval of epcoritamab as a treatment for patients with relapsed/refractory DLBCL not otherwise specified, including indolent lymphoma and high-grade B-cell lymphoma.

Tycel Phillips, MD, shares...

07/06/2023

Oncology

Videos

BTK Inhibitors in Combination With Other Therapies as First-Line Treatment for Patients With Mantle Cell Lymphoma

06/27/2023

Featuring Vincent Ribrag, MD

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

At the 2023 EHA Congress,...

06/27/2023

Oncology

Videos

Acalabrutinib Combined With Bendamustine and Rituximab for Patients With Treatment-Naive or Relapsed/Refractory MCL

06/26/2023

Featuring Tycel Phillips, MD

Tycel Phillips, MD, presented data at the 2023 ASCO annual meeting on the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab among patients with treatment-naive or R/R mantle cell lymphoma.

Tycel Phillips, MD, presented...

06/26/2023

Oncology

Carlotta Antoniotti, MD, PhD, University of Pisa

Videos

Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-Line Setting

06/22/2023

Featuring Carlotta Antoniotti, MD, PhD

Featuring Carlotta Antoniotti, MD, Ph...

At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.

At the 2023 ASCO annual meeting,...

06/22/2023

Oncology

Videos

Ibrutinib Dose Adjustments in the Frontline Treatment of Patients With CLL

06/22/2023

Featuring Kerry Anne Rogers, MD

Featuring Kerry Anne Rogers, MD ...

At the 2023 ASCO Annual Meeting in Chicago, Illinois, Kerry Anne Rogers, MD, provided insights into real-world dosing ibrutinib patterns and outcomes among patients with chronic lymphocytic leukemia.

At the 2023 ASCO Annual Meeting...

06/22/2023

Oncology

Omid Hamid, MD, The Angeles Clinic & Research Institute

Videos

Fianlimab Plus Cemiplimab Induces High Clinical Activity Response for Patients With Advanced Melanoma

06/21/2023

At the 2023 ASCO Annual Meeting, Omid Hamid, MD, shares results from a trial examining the combination treatment of fianlimab plus cemiplimab for patients with advanced melanoma.

At the 2023 ASCO Annual Meeting,...

06/21/2023

Oncology

Javier Cortes, MD, PhD, International Breast Cancer Center, Madrid, Spain

Videos

Chemotherapy De-escalation for HER2-Positive Early Breast Cancer

06/21/2023

Javier Cortes, MD, PhD, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.

Javier Cortes, MD, PhD,...

06/21/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology